Myelodysplastic Syndrome Pipeline Therapeutic Drugs and Companies Review H1 2017 Research Report Available at RnRMarketResearch

Wednesday, June 21, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

PUNE, India, June 21, 2017 /PRNewswire/ -- adds "Myelodysplastic Syndrome Pipeline Review H1

2017" therapeutic market research report provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.

The report Myelodysplastic Syndrome - Pipeline Review H1 2017 provides comprehensive information on

the therapeutic development for Myelodysplastic Syndrome. Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

Myelodysplastic Syndrome Pipeline is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Companies discussed in this report include: 4SC AG, AbbVie Inc, Acceleron Pharma Inc, Actinium Pharmaceuticals Inc, Aeglea BioTherapeutics Inc, Agios Pharmaceuticals Inc, Aileron Therapeutics Inc, Altor BioScience Corp, Amgen Inc, Apogenix GmbH, Aprea AB, arGEN-X BV, Ariad Pharmaceuticals Inc, Arno Therapeutics Inc, Array BioPharma Inc, Astex Pharmaceuticals Inc, Atara Biotherapeutics Inc, Bayer AG, Bellicum Pharmaceuticals Inc, BerGenBio ASA, Bio-Path Holdings Inc, BioLineRx Ltd, BioLite Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences Inc, Cantex Pharmaceuticals Inc, Celgene Corp, Celldex Therapeutics Inc, Cellectis SA, Cellerant Therapeutics Inc, Celyad SA, Cornerstone Pharmaceuticals Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, Deciphera Pharmaceuticals LLC, Eisai Co Ltd, Eleos Inc, Eli Lilly and Company, EpiZyme Inc, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, Forma Therapeutics Inc, Fortress Biotech Inc, Fujifilm Corp, Gamida Cell Ltd, GlaxoSmithKline Plc, H3 Biomedicine Inc, IGF Oncology LLC, Immune System Key Ltd, ImmunoGen Inc, Incyte Corp, Io Therapeutics Inc, Jazz Pharmaceuticals Plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Johnson & Johnson, JW Pharmaceutical Corp, Kainos Medicine Inc, KaloBios Pharmaceuticals Inc, Karyopharm Therapeutics Inc, Kiadis Pharma NV, Kyowa Hakko Kirin Co Ltd, Les Laboratoires Servier SAS.

Order a Copy of this report @ . (This is a premium report priced at US$2000 for a single user License.)

Scope of this report includes: a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Myelodysplastic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products.

Related report:

Myelodysplastic Syndrome- Market Insights, Epidemiology and Market Forecast-2023  

Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Myelodysplastic Syndrome forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Myelodysplastic Syndrome till 2023.

Complete report available at: .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Ritesh Tiwari 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001 Tel: +1-888-391-5441

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

SOURCE RnRMarketResearch

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store